Virtual Library
Start Your Search
Y. Sasahara
Author of
-
+
P2.03 - Chemotherapy/Targeted Therapy (ID 704)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.03-032 - Efficacy and Safety of Osimertinib as Third-Line or Later Therapy for T790M-Positive Advanced Non-Small Cell Lung Cancer (ID 9172)
09:30 - 09:30 | Author(s): Y. Sasahara
- Abstract
Background:
Advanced lung adenocarcinoma with epidermal growth factor receptor (EGFR) gene mutation in exon 18 to 21 is sensitive to EGFR tyrosine kinase inhibitors (TKI) such as gefitinib, erlotinib, and afatinib. However acquired resistance to EGFR-TKI develops after initial treatment, primarily due to T790M mutation. In March 2016, the Japanese Ministry of Health, Labour and Welfare approved osimertinib for the patients with advanced non-small cell lung cancer harboring a T790M mutation. In the same year, patients with a T790M secondary mutation were reviewed at Hiratsuka Kyosai Hospital for a period of 9 months. All patients were previously treated with an EGFR-TKI (with or without or prior/subsequent chemotherapy).
Method:
Data were obtained retrospectively by analysis of the medical records of patients who underwent molecular diagnostic testing for T790M mutation. All patients had stage IV adenocarcinoma.
Result:
A total of 8 patients with T790M mutation were identified. Molecular testing was performed using re-biopsy specimens of the primary tumor, metastatic lymph node, or circulating DNA in the plasma of patients. Seven out of 8 patients received osimertinib 80mg once daily. All patients treated with osimertinib received other treatments previously, including EGFR-TKI and standard chemotherapy. The overall response rate (ORR) was 87%. Most common adverse events included diarrhea (28.6%), rash (14.2%), nausea (14.2%). Adverse events of Grade 3 to 4 severity were not reported.
Conclusion:
These findings suggest that third-line or later osimertinib for advanced lung adenocarcinoma with T790M results in high ORR and managed tolerability. The use of molecular testing may improve treatment outcome in these patients.
